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INTRODUCTION: Apolipoproteins play a role in regulating cholesterol transportation 
and clearance with each apolipoprotein having a protective or atherogenic role. However, 
previous literature in youth have insufficiently described the relationship between each 
apolipoprotein variable and subclinical cardiovascular risk. Hence, the purpose of this 
study was to examine the association of apolipoproteins with measures of vascular 
structure and function in children and adolescents. 
METHODS: A cross-sectional study of 338 youth (160 males, 178 females; mean age = 
13.0±2.8 years) with a range of adiposities from normal body weight to severe obesity. 
Apolipoproteins (AI, AII, B100, CII, CIII, and E) were measured via human 
apolipoprotein magnetic bead panel. Ultrasound imaging of the carotid artery was used to 
measure carotid intima-media thickness (cIMT), carotid cross-sectional compliance 
(cCSC), carotid diameter compliance (cDC), carotid cross-sectional distensibility 
(cCSD), carotid diameter distensibility (cDD), and carotid incremental elastic modulus 
(cIEM). Applanation tonometry assessed pulse wave velocity (PWV). Dual X-ray 
absorptiometry measured total body fat percent. Linear regression models were adjusted 
for Tanner stage, sex, and race with further adjustments for body fat percent. Data are 
presented as mean [95% CI] with Holm’s-adjusted p-values to account for multiple 
testing. All apolipoproteins were scaled to 10 µg/mL and apolipoprotein ratios were 
scaled to 0.1 µg/mL. 
RESULTS: Prior to accounting for multiple testing, apolipoprotein CIII:CII ratio was 
positively associated with cIMT (0.001 [0, 0.003], p = 0.033), but failed to maintain 
significance after p-value correction. Otherwise, there were no significant associations 
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between any apolipoprotein and cIMT, cCSC, cDC, cCSD, cDD, and cIEM in the 
presence or absence of body fat percent. There were significant positive associations 
between PWV and apolipoproteins: AII (0.04 m/sec [0.02, 0.06], p = 0.046) and E (0.16 
m/sec [0.08, 0.24], p = 0.012). After adding body fat percent to the models, PWV 
remained positively associated with higher levels of apolipoproteins E (0.16 m/sec [0.08, 
0.24], p = 0.01). 
CONCLUSIONS: These findings suggest higher levels of apolipoprotein E are 
associated with higher arterial stiffness (PWV) in pediatrics, both in the presence and 
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CHAPTER 1: INTRODUCTION 
The pathophysiology leading to cardiovascular disease begins in childhood and is 
accelerated by advancing age, male sex, dyslipidemia, hypertension, obesity, and tobacco 
smoking (Berenson et al., 1998; Dengel & Bronas, 2010; O’Rourke, Staessen, 
Vlachopoulos, Duprez, & Plante, 2002; Rainwater et al., 1999). Specifically, maintaining 
normal levels of cholesterol is one of the many factors essential for the prevention of 
cardiovascular disease. Apolipoproteins (APO) are formed predominately in the liver and 
intestine, and they play an essential role in the production and transportation of 
cholesterol around the body (Donma & Donma, 1989). There are a variety of APOs (e.g., 
AI, AII, B100, CII, CIII, and E), with each type binding to either high-density lipoprotein, 
low-density lipoprotein, very-low-density lipoprotein, or chylomicrons in the blood. 
Depending on the concentrations of each APO, there may be more atherogenic properties 
(i.e., B100, CIII, E) or protective properties (i.e., AI, AII, CII), thereby affecting vascular 
structure and function (Dengel & Bronas, 2010). Notably, decreases in endothelial 
function play an essential role in the progression of atherosclerosis and is considered a 
marker of subclinical cardiovascular disease (Anderson et al., 1995; Vrints, Bult, 
Bosmans, Herman, & Snoeck, 1992; Yasue et al., 1990; Zeiher, Drexler, Wollschläger, & 
Just, 1991). Therefore, APOs may have a direct impact on the risk of cardiovascular 
disease.  
 Previous literature on the association of APO variables and cardiovascular disease 
risk factors have primarily been in adults (Gerber, Goldbourt, Cohen, & Harats, 2002; 
Huang et al., 2013; Ooi, Barrett, Chan, & Watts, 2008; Sacks et al., 2000; Schaefer et al., 
1994; Steffen et al., 2017) while recent literature in children has primarily been focused 
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on differences in APO-AI and APO-B100 concentrations. Some studies report associations 
of APO-AI and APO-B100 across body mass index (BMI) in children (Hobkirk et al., 
2014; Krekoukia et al., 2007; Teixeira, Sardinha, Going, & Lohman, 2001). Specifically, 
these studies report lower levels of APO-AI and higher levels of APO-B100 in children 
with obesity compared to their counterparts without obesity (Krekoukia et al., 2007; 
Teixeira et al., 2001). This is important since vascular structure and function are affected 
by childhood obesity and may increase the risk of cardiovascular disease (Burke et al., 
2008; Kotis et al., 2006; Steinberg et al., 1996; Tounian et al., 2001; Williams et al., 
2005; Woo et al., 2004). Previous studies in children have explored the association of 
APO-AI and APO-B100 and carotid intima-media thickness (cIMT). They have reported 
that adulthood cIMT was inversely related to APO-AI and directly related with APO-B100 
(Frontini et al., 2008; Kallio et al., 2010; Juonala et al., 2008). To date, few studies have 
examined APO concentrations in relation to vascular function in children (Juonala et al., 
2008; Tounian et al., 2001). Particularly, these researchers examined the relationship 
between APO-AI and flow-mediated dilation in children, a measure of endothelial 
dysfunction. They observed a strong positive correlation between flow-mediated dilation 
and APO-AI concentration in both children with normal weight and children with obesity 
(Juonala et al., 2008; Tounian et al., 2001). These results indicated a possible relationship 
between low APO-AI levels and endothelial dysfunction in children. Therefore, while 
previous studies have explored APO-AI and APO-B100 concentrations in children and 
adolescents, these studies have not examined other APO concentrations (i.e., AII, CII, 
CIII, E). Consequently, more research on the APO variables (i.e., AI, AII, B100, CII, CIII, 
E) in children and adolescents and their potential association with subclinical 
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cardiovascular risk is warranted. The purpose of this study was to examine the 
association of APOs with measures of vascular structure and function among children 
and adolescents.  
The following chapters of this thesis include a literature review, methodological 
explanations, results summary, discussion, and conclusion. 
Chapter two summarizes the current literature related to apolipoprotein function. 
Measurement techniques to examine subclinical cardiovascular disease will be described. 
Additionally, the relationship between apolipoproteins and cardiovascular disease in 
adults and children will be explored.  
Chapter three includes details on the study’s methodology including information 
on the study population; procedures and measurement techniques, including 
anthropometric, blood pressure, blood assay, and vascular assessments; and statistical 
analyses. 
Chapter four summarizes the results of the study. Associations of each 
apolipoprotein variable between measures of vascular structure and function. 
Chapter five includes a discussion of study results. Findings are presented in 
regard to previously published studies related to the current topic. 







CHAPTER 2: LITERATURE REVIEW 
Apolipoproteins 
What Are Apolipoproteins? 
APOs are major proteins that assist in the production, transportation, and 
clearance of cholesterol. There are a variety of APOs (e.g., AI, AII, B100, CII, CIII, and 
E), with each type binding to either high-density lipoprotein, low-density lipoprotein, 
very-low-density lipoprotein, or chylomicrons (Donma & Donma, 1989; Schaefer, 
Eisenberg, & Levy, 1978). In lipoprotein metabolism, APOs have a variety of roles. 
These include acting as structural proteins for lipoproteins, cofactors for enzymes, and 
ligands for binding to cell-surface receptors (Rader et al., 1994). 
APO-AI is the major protein component of high-density lipoprotein and minor 
component of chylomicrons and very-low-density lipoproteins. It assists in the activation 
of lecithin-cholesterol acyltransferase (Schaefer et al., 1978; Tian & Fu, 2011). APO-AI 
plays a major role in reverse transport of cholesterol to the liver. This process is done by 
APO-AI removing excess cholesterol from tissues and incorporating it into high-density 
lipoprotein cholesterol (Erdeve, Simsek, Dallar, & Biyikli, 2010). Similarly, APO-AII is 
the second most abundant protein in high-density lipoprotein. However, the specific roles 
of APO-AII in high-density lipoprotein metabolism are complex and have been 
controversial (Tailleux, Duriez, Fruchart, & Clavey, 2002). The roles for APO-AII 
include acting as an activator of hepatic lipase, inhibitor of cholesteryl ester transfer 
protein, and inhibitor of lecithin-cholesterol acyltransferase (Tian & Fu, 2011, Rader et 
al., 1994). Inhibition of lecithin-cholesterol acyltransferase may be a potential harmful 
effect. Whereas inhibition of cholesteryl ester transfer protein and activation of hepatic 
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lipase may be a potential beneficial effect. Therefore, the opposing roles in lipoprotein 
metabolism provide conflicting evidence in regard to whether APO-AII is antiatherogenic 
or proatherogenic.   
On the other hand, APO-B100 is a major protein component of low-density 
lipoproteins, very-low density lipoproteins, and chylomicrons. There is only one APO-
B100 particle per particle—very-low-density lipoprotein, intermediate-density lipoprotein, 
and low-density lipoprotein—with these particles having atherogenic properties 
(Walldius & Jungner, 2007). The major role of APO-B100 is triglyceride transport 
(Schaefer et al., 1978). In metabolism, APO-B100 combines with cholesterol and 
triglycerides to produce very-low-density lipoproteins. Likewise, the APO-B100:AI ratio 
reflects the cholesterol balance. Particularly, the ratio between potentially atherogenic 
lipoproteins and antiatherogenic lipoproteins (Walldius & Jungner, 2007). However, 
higher levels of APO-B100 does not mean low levels of APO-AI 
In addition, APO-CII and APO-CIII are protein components of chylomicrons, 
very-low-density lipoprotein, and high-density lipoprotein. APO-CII plays a role in 
lipoprotein lipase activation (Kei, Filippatos, Tsimihodimos, & Elisaf, 2012; Schaefer et 
al., 1978; Tian & Fu, 2011). On the other hand, APO-CIII plays a role in inhibition of 
lipoprotein lipase, lipoproteins binding to receptors, and regulates the uptake of 
triglyceride-rich lipoprotein remnants via hepatic receptors (Ooi et al., 2008; Rader et al., 
1994; Schaefer et al., 1978; Tian & Fu, 2011).  
Lastly, APO-E is a protein component of very-low-density lipoprotein and high-
density lipoprotein. It is a ligand for binding to low-density lipoprotein receptor (Rader et 
al., 1994). In addition, APO-E assists as a ligand for clearance of the lipoproteins 
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containing APO-B. However, it does not aid in the clearance of low-density lipoproteins. 
Additionally, the APO-E gene is polymorphic with three alleles (i.e., e2, e3, e4) 
(Davignon, Gregg, & Sing, 1988; Utermann, Hardewig, & Zimmer, 1984). Previous 
research has reported that allele phenotype impacts cholesterol levels. For example, e2 
has been observed to correspond with lower low-density lipoproteins levels, where e4 has 
been observed to correspond with higher low-density lipoprotein levels. Also, the e4 
allele has been observed to increase the risk of cardiovascular disease compared to other 
individuals expressing the e2 and e3 allele (Davignon et al., 1988; Kolovou, Daskalova, 
& Mikhailidis, 2003; Song, Stampfer, & Liu, 2004; Utermann et al., 1984). Ultimately, 
the e4 allele could favor the development of atherosclerosis (Doliner et al., 2018; Slooter 
et al., 2001; Volcik et al., 2006). 
 
 
Effect of Age on Apolipoproteins 
Previous literature has reported inconsistent results on the effect of age on each 
APO. Concentrations of APO-AI have been reported to increase (Anagnostis, Stevenson, 
Crook, Johnston, & Godsland, 2016, Sniderman et al., 2016), decrease (Anagnostis et al., 
2016), and remain the same with increasing age (Sakurabayashi, Saito, Kita, Matsuzawa, 
& Goto, 2001). However, it has been noted that women consistently have higher APO-AI 
concentrations compared to men (Anagnostis et al., 2016; Sakurabayashi et al., 2001). 
Whereas, APO-AII concentrations have been reported to increase with age in women and 
decrease with age in men (Anagnostis et al., 2016; Sakurabayashi et al., 2001). Similarly, 
APO-B100 concentrations have been reported to either increase with increasing age 
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(Anagnostis et al., 2016; Sakurabayashi et al., 2001) or remain the same (Sniderman et 
al., 2016). Due to the conflicting results of the impact of age with APO-AI and APO-
B100, the APO-B100:AI has also been reported to either decrease or increase with age 
(McQueen et al., 2008; Sakurabayashi et al., 2001; Sniderman et al., 2007). Previous 
research has observed the levels of both APO-CII and APO-CIII to increase with age 
(Sakurabayashi et al., 2001). Lastly, a previous study reported an increase in APO-E with 
age. Also, women had higher concentrations of APO-E compared to men regardless of 
age (Sakurabayashi et al., 2001). While these previous studies explore the relationship of 
age on APO concentrations, these studies were conducted in individuals over 20 years 
old, with participants predominatley being middle age and older. Therefore, more 
research is needed to determine the effect of age, including children and adolescents. 
 
Effect of Body Fat on Apolipoproteins 
Previous research conducted exploring the relationship between body fat and 
APO concentrations have predominately been in APO-AI, APO-B100, APO-CII, and the 
APO-B100:AI ratio (Anagnostis et al., 2016; Kallio et al., 2010; Karabouta, Papandreou, 
Makedou, Rousso, & Athanassiadou, 2016). Notably, children with obesity had lower 
APO-AI levels compared to their normal weight peers (Karabouta et al., 2016). Previous 
research has also reported that a higher BMI was associated with higher APO-B100 and 
APO-B100:AI ratio (Anagnostis et al., 2008). Other research exploring the effect of body 
fat and APOs, specifically APO-AI and APO-B100, have been conducted in individuals 
with and without the metabolic syndrome (Alemzadeh & Kichler, 2018; Erdeve et al., 
2010). Individuals with the metabolic syndrome had significantly lower levels of APO-AI 
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and higher levels of APO-B100 and APO-B100:AI ratio compared to individuals without 
the metabolic syndrome (Alemzadeh & Kichler, 2018; Erdeve et al., 2010). Therefore, 
body fat may have an effect on the concentrations of each APO. However, more research 
is needed to explore how body fat impacts all of the APO variables. 
 
Cardiovascular Disease 
Arterial stiffness is an important factor in the progression of cardiovascular 
disease. In addition, two major determinants of arterial stiffness are collagen and elastin. 
Specifically, vascular stiffness occurs from an overproduction of abnormal collagen and 
reduced normal elastin (Laurent et al., 2006). While there are molecular and cellular 
factors of arterial stiffness, there are also clinical conditions associated with increased 
arterial stiffness. These include advancing age, physiological conditions (i.e., lack of 
physical activity), genetic background (i.e., parental history of myocardial infarction), 
cardiovascular risk factors (i.e., obesity, smoking, hypertension), and cardiovascular 
diseases (i.e., coronary heart disease) (Laurent et al., 2006). Therefore, understanding 
factors that affect arterial stiffness is important because arterial stiffness is a subclinical 
marker of cardiovascular risk. 
 
Effect of Age on Cardiovascular Disease 
To determine the effect of age, especially early studies in children, autopsy 
studies have been the primary sources for showing the progression of cardiovascular 
disease. Autopsy studies have shown that fatty streaks in the coronary arteries increase 
with age (Berenson et al., 1998). Importantly, these studies have shown that 
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atherosclerosis begins in childhood. In addition, while atherosclerosis begins in 
childhood, it progresses with age. Therefore, there is an increased risk of atherosclerosis 
and cardiovascular disease with increasing age (Sniderman et al., 2016). This is due to an 
increase in collagen while there is a subsequent decrease in elastic fibers (Laurent et al., 
2006). Thus, there is a worsening of endothelial dysfunction—a decrease in the ability of 
the artery to constrict or dilate in response to various physical and chemical stimuli 
(Dengel & Bronas, 2010). In subclinical atherosclerosis, endothelial dysfunction may 
occur prior to the thickening of the vascular wall (Kallio et al., 2010). A decrease in 
function before structural changes is the most common progression of the 
pathophysiology of atherosclerosis. 
 
Effect of Body Fat on Cardiovascular Disease 
While age is a non-modifiable factor that impacts cardiovascular disease, body fat 
is another factor that affects cardiovascular disease. Autopsy studies have reported a 
positive correlation with atherosclerotic lesions and BMI (Berenson et al., 1998). 
Research in children and adolescence exploring the relationship in body fat and non-
invasive measures of cardiovascular disease, have reported that obesity in adolescence 
predicts a broad range of later health problems (Tounian et al., 2001). This includes early 
indications of decreased vascular structure and function. This was seen with a decrease in 
cross-sectional compliance and distensibility and flow-mediated dilation in the arteries 
(Tounian et al., 2001; Williams et al., 2005; Woo et al., 2004). In addition, there was an 
increase in carotid incremental elastic modulus (cIEM) and cIMT (Burke et al., 2008; 
Kotsis, Stabouli, Papamichael, & Zakopoulos, 2006; Tounian et al., 2001; Woo et al., 
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2004). These risks for cardiovascular disease become more pronounced in individuals 
whom are overweight and with obesity (Karabouta et al., 2016). Therefore, increases in 
adiposity are associated with increased risk for cardiovascular disease (Lloyd-Jones et al., 
2006). 
 
Subclinical Measures of Atherosclerosis 
The pathophysiology of atherosclerosis results in changes in both vascular 
structure and function that occur prior to the clinical diagnosis. However, there are 
various techniques to measure subclinical atherosclerosis non-invasively, which include 
cIMT, compliance (i.e., cross-sectional compliance [CSC], diameter compliance [DC]), 
distensibility (i.e., cross-sectional distensibility [CSD], diameter distensibility [DD]), 
cIEM, and pulse wave velocity (PWV). cIMT is a marker of structural atherosclerosis, 
with increased thickness considered an independent risk factor of cardiovascular disease 
(Juonala et al., 2008).  In addition, arterial elasticity is determined by how well the artery 
can return to its previous shape after a deforming force or stress (Marlatt, Kelly, 
Steinberger, & Dengel, 2013). Arterial elasticity can be measured by compliance, 
distensibility, and IEM. Compliance is the change in volume prompted by a change in 
pressure and relates the artery as a hollow structure to provide information about the 
elasticity (Aggoun et al., 2000; Jani & Rajkumar, 2006; Reneman, Meinders, & Hoeks, 
2005). Whereas distensibility is the change in arterial volume in contrast to the change in 
pressure (Reneman et al., 2005). Compared to compliance, distensibility relates more to 
wall stiffness relative to initial volume (Marlatt et al., 2013). While, IEM indicates 
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properties of the arterial wall independent of geometry (Aggoun et al., 2000; Tounian et 
al., 2001).  
Pulse-wave velocity (PWV) measures arterial stiffness via applanation tonometry. 
The pulse wave is assessed between two sites (i.e., radial-carotid, femoral-carotid) in the 
line of pulse travel. The delay between the R-wave determined by the three-lead 
electrocardiogram (ECG) and the initial upstroke of the pulse wave is the point of 
reference for PWV quantification (Laurent et al., 2006; O’Rourke et al., 2002).  
 
Apolipoproteins and Cardiovascular Disease 
The risk of cardiovascular disease starts in childhood and progresses through 
adulthood. Similarly, a crucial role in the pathogenesis of atherosclerosis is the 
interaction between lipoproteins and endothelial cells (Bornaun et al., 2017). Depending 
on the concentrations of each APO, there may be more atherogenic properties (i.e., B100, 
CIII, E) or protective properties (i.e., AI, AII, CII), thereby affecting vascular function. 
Specifically, decreases in vascular function play a critical role in the development of 
atherosclerosis (Anderson et al., 1995; Vrints et al, 1992; Yasue et al., 1990; Zeiher et al., 
1991). However, APOs and APO ratios (i.e., B100:AI) may be more sensitive and specific 
biomarkers compared to the use to lipids or lipoproteins for the assessment of 
cardiovascular disease risk (Donma & Donma, 1989). 
Previous literature on the association of APO variables and cardiovascular disease 
risk factors have primarily been in adults (Gerber et al., 2002; Huang et al., 2013; Kei et 
al., 2012; Ooi et al., 2008; Sacks et al., 2000; Schaefer et al., 1994; Sniderman et al., 
2007, 2016; Steffen et al., 2017; Stewart et al., 2007; Zivanovic et al., 2018). Previous 
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research in adults have reported that increased APO-B100 and APO-CII and decreased 
APO-AI and APO-E may play a role in the risk of cardiovascular disease (Kei et al., 
2012; Sniderman et al., 2007; Stewart et al., 2007). In addition, previous literature in 
adults have explored the differences in APO concentrations in individuals who have had 
a myocardial infarction compared to healthy controls. These studies have reported that 
individuals who had a myocardial infarction had lower APO-AI and APO-AII and higher 
APO-B100 and APO-B100:AI ratio compared to the controls (Kappelle, Gansevoort, 
Hillege, Wolffenbuttel, & Dullaart, 2011; McQueen et al., 2008; Pischon et al., 2005; 
Sharrett et al., 1994; Sniderman et al., 2016). Likewise, literature in adults have explored 
the association between APOs and cIMT. These researchers observed that patients with 
increased cIMT had lower mean APO-AI and higher mean APO-B100 and APO-B100:AI 
ratio (Sharrett et al., 1994; Zivanovic et al., 2018). Notably, they reported the APO-
B100:AI ratio as the most significant predictor of increased cIMT (Wallenfeldt, 
Bokemark, Wikstrand, Hulthe, & Fagerberg, 2004; Zivanovic et al., 2018). Indicating 
that the ratio of APO-B100:AI may be a strong predictor of atherosclerotic disease. 
On the other hand, recent research in children has primarily been focused on 
differences in APO-AI and APO-B100 concentrations. Studies conducted have primarily 
explored the relationship between APO concentrations in children of parents who had 
either early onset coronary heart disease, history of cardiovascular disease, or myocardial 
infarction. These studies reported children of patients had lower concentrations of APO-
AI and APO-AII, and higher APO-B100 and APO-B100:AI ratio (Beigel et al., 1993; 
Bornaun et al., 2017; Freedman et al., 1986; Uiterwaal et al., 1996). In addition, previous 
studies in children have explored APO-AI and APO-B100 concentrations across BMI 
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(Hobkirk et al., 2014; Krekoukia et al., 2007; Teixeira et al., 2001). These studies report 
associations of APO-AI and APO-B100 with adiposity. Specifically, lower levels of APO-
AI and higher levels of APO-B100 in children with obesity compared to their counterparts 
without obesity (Krekoukia et al., 2007; Teixeira et al., 2001). This is important since 
vascular structure and function are affected by childhood obesity and may increase the 
risk of cardiovascular disease (Dengel & Bronas, 2010).  
To date, few studies have examined APO concentrations in relation to vascular 
function in children (Juonala et al., 2008; Tounian et al., 2001). Studies in children with 
obesity have reported a positive correlation between flow-mediated dilation and APO-AI 
concentration (Tounian et al., 2001). In addition, APO-AI was directly related to 
adulthood flow-mediated dilation (Juonala et al., 2008). Indicating a possible relationship 
between low APO-AI levels and endothelial dysfunction in children and the potential 
future effects of APO concentrations. While flow-mediated dilation is another measure of 
vascular function, specifically endothelial dysfunction, it was not a measure in the present 
study. 
Likewise, few studies have explored the association between APOs and cIMT in 
children (Frontini et al., 2008; Juonala et al., 2008; Kallio et al., 2010). Specifically, the 
studies conducted by Juonala and colleagues (2008) and Frontini and colleagues (2008) 
were the most similar to the current study. Their purpose was to determine if APO-AI and 
APO-B100 measured in childhood predicts atherosclerosis risk in adulthood. Their 
participants were part of the Cardiovascular Risk in Young Finns Study and the Bogalusa 
Heart Study, respectively. They measured APO-AI and APO-B100 during childhood and 
cIMT in adulthood of the same participants. The first study observed APO-AI was 
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inversely related and APO-B100 and APO-B100:AI ratio were directly related to adulthood 
cIMT (Juonala et al., 2008). Whereas the other study observed that APO-B100 and APO-
B100:AI ratio was a significant predictor of excess cIMT in adulthood (Frontini et al., 
2008). Both studies concluded that these APOs measured in childhood predict increased 
cIMT in adulthood.  
Therefore, while previous studies have explored APO-AI and APO-B100 
concentrations in children and adolescences, these studies have not examined other APO 
concentrations (i.e., AII, CII, CIII, E). The information derived from this literature review 
substantiates the need for more research on the APO variables (i.e., AI, AII, B100, CII, 
CIII, E) in children and adolescents and their potential association with subclinical 
atherosclerosis is warranted. The purpose of this study is to examine the association of 
APOs (i.e., AI, AII, B100, CII, CIII, E) with measures of vascular structure and function 
(i.e., cIMT, cCSC, cDC, cCSD, cDD, cIEM, PWV) among children and adolescents. We 
hypothesize that APO concentrations will have a significant correlation with many 
subclinical cardiovascular disease risk factors. 
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CHAPTER 3: METHODS 
Subject Population 
This cross-sectional study included 338 children and adolescents (160 male/178 
female) aged 8 to 17 years from the Minneapolis and St. Paul metropolitan area. 
Participants were recruited from various pediatric clinics, including the University of 
Minnesota Masonic Children’s Hospital Pediatric Weight Management Clinic 
(participants with obesity or severe obesity only) between 2011-2016. Exclusion from 
study participation included untreated obstructive sleep apnea, obesity due to a genetic 
cause, previous medical history of weight loss surgery, current use of antihypertensive 
medications, type 1 diabetes mellitus, history of hypercholesterolemia, chronic kidney 
disease or end-stage renal disease, Kawasaki disease, autoimmune inflammatory diseases, 
and congenital heart disease. Parents and participants provided informed consent and 
assent, respectively. Study approval was given by the University of Minnesota 
Institutional Review Board. 
Anthropometric Measurements and Pubertal Maturation  
Testing was conducted at the University of Minnesota. Height was measured 
using a wall-stadiometer and weight was measured using a calibrated electronic scale. 
BMI was calculated by using body mass in kilograms (kg) divided by height in squared 
meters (m2). Body composition was measured using standard procedures in the total-body 
supine position using dual X-ray absorptiometry (iDXA; General Electronic Medical 
Systems, Madison, WI, USA) and data were analyzed using enCore software version 
(platform version 16.0, General Electric Medical Systems, Madison, WI). Age and race 
were self-reported; race was categorized as non-Hispanic White, Latino/Hispanic, Black, 
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or other. Sex and pubertal stage were determined by a pediatrician or trained nurse using 
standard Tanner staging procedures (Tanner & Whitehouse, 1976).  
Measurement of Lipids and Apolipoprotein Levels 
Fasting blood samples (>10 hours) were collected and lipids (total cholesterol, 
low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, 
glucose, and insulin) were measured using standard methods in the Fairview Diagnostics 
Laboratories, Fairview-University Medical Center (Minneapolis, MN, USA), a Center for 
Disease Control and Prevention certified laboratory. In addition, APO variables (i.e., AI, 
AII, B100, CII, CIII, and E) were measured with the MILLIPLEX MAP Human 
Apolipoprotein Magnetic Bead Panel kit (Millipore, MA, USA).  
Ultrasound-derived Measures of Arterial Structure and Elasticity 
Images of the left carotid artery were obtained via ultrasound (Acuson, Seuoia 
512, Siemens Medical Solutions USA, Inc., Mountain View, CA, USA) with an 8.0-15.0 
MHz linear array probe. Following 15 minutes of supine rest, luminal systolic and 
diastolic diameters of the imaged artery were obtained in the longitudinal plane and at a 
fixed point. The left carotid artery was imaged approximately 1 centimeter proximal from 
the carotid bulb. Images were collected at 20 frames per second for 10 seconds, 
concurrently with the measurement of peripheral systolic blood pressure, diastolic blood 
pressure, and cIMT. All artery images were analyzed using an off-line, electronic wall-
tracking software program (Vascular Research Tools 6, Medical Imaging Application, 
LLC, Iowa city, IA, USA). Mean diameter through the recording was used to calculate 
both distensibility and compliance. The following calculations were used for arterial 
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cross-sectional compliance (CSC), diameter compliance (DC), cross-sectional 
distensibility (CSD), diameter distensibility (DD), and IEM: 
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Where minDiamM is the minimum (diastolic) arterial diameter, maxDiamM is the 
maximum (systolic) arterial diameter, minDiamI is the minimum lumen diameter, and 
pulse pressure (∆P) is calculated as the difference between systolic and diastolic blood 
pressure (Aggoun et al., 2000; Laurent et al., 2006; Marlatt et al., 2013). 
Measurement of Arterial Stiffness 
Pulse waveforms were obtained using an arterial tonometer placed over the 
strongest radial and carotid pulse points relative to the sternal notch. These waveforms 
were timed to ventricular depolarization via a three-lead ECG. Calculations were made 




Descriptive statistics were calculated for the participants. Linear regression 
models assessed the association of each APO variable with measures of vascular structure 
and function (i.e., cIMT, cCSC, cDC, cCSD, cDD, cIEM, and PWV). Linear regression 
models were adjusted for Tanner stage, sex, and race with further adjustments for body 
fat percentage. Data are presented as mean [95% CI] with Holm’s-adjusted p-values to 





CHAPTER 4: RESULTS 
 A total of 338 participants (160 males, 178 females) were examined in this study 
(Table 1). The average age for the participants was 13.0±2.77 years and included 
individuals from Tanner stage I-V.  In addition, while the mean height was 157±14.1 cm 
and the mean weight was 68.6±29.9 kg, there was a wide range of BMIs. Participants 
were categorized into four BMI groups: Normal Weight (n=132), Overweight (n=24), 
Obesity (n=69), and Severe Obesity (n=113). Race was self-reported and included the 
following groups: African American or Black (n=34), White (n=260), Latino/Hispanic 
(n=38), and Other (n=44). 
The associations of cIMT, cCSC, cDC, cCSD, cDD, cIEM, and PWV with each 
APO (AI, AII, B100, CII, CIII, E, and the ratio of B100:AI and CIII:CII) adjusted for 
Tanner stage, sex, and race are displayed in Table 2-8, and is denoted as model 1. Prior to 
post-hoc adjustment, statically significant, inverse association between cIMT and APO-
CII (-0.003 m/sec per 10 µg/mL [-0.005, 0], p=0.02), and a positive association between 
cIMT and APO-CIII:CII ratio (0.001 [0, 0.003], p=0.033) was observed. However, both 
associations failed to maintain statistical significance after p-value correction accounting 
for multiple testing. Prior to post-hoc adjustment there were statistically significant, 
positive association between PWV and APOs: AI (0.02 m/sec per 10 µg/mL [0.01, 0.03], 
p=0.003), AII (0.04 m/sec per 10 µg/mL [0.02, 0.06], p<0.001), B100 (0.01 m/sec per 10 
µg/mL [0.002, 0.02], p=0.012), E (0.16 m/sec per 10 µg/mL [0.08, 0.24], p<0.001), and 
CIII:CII ratio (0.03 [0.01, 0.05], p<0.001). After adjusting for multiple testing, PWV was 
statistically significantly associated with APO-AII (0.04 m/s per 10 µg/mL [0.02, 0.06] 
p=0.046) and APO-E (0.16 m/s per 10 µg/mL [0.08, 0.24], p=0.012). There were no 
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statistically significant associations between any of the apolipoproteins and cIMT, cCSC, 
cDC, cCSD, cDD, and cIEM.  
We conducted further multiple linear regression analysis to account for any effect 
of body fatness (body fat percent) (Tables 2-8, model 2). Following adjustment for body 
fat percent, PWV remained significantly, positively associated with higher levels of 
APO-E (0.16 m/sec per 10 µg/mL [0.08, 0.24], p=0.01). There were no significant 
associations between any APO and cIMT, cCSC, cDC, cCSD, cDD, or cIEM.  
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CHAPTER 5: DISCUSSION 
To the best of our knowledge, the current study is the first to examine the 
association of multiple APOs to measures of vascular structure and function in a pediatric 
population. The most important study observations included statistically significant 
associations in APO-E with PWV, both with and without the adjustment of percent body 
fat. Surprisingly, although there were associations in APOs and PWV, there were no 
significant associations with cIMT, cCSC, cDC, cCSD, cDD, or cIEM. Taken together, 
results from the present study indicate that APOs, specifically APO-E, may exert its 
effects on vascular function before altering vascular structure, though longitudinal studies 
assessing the chronology will be needed to confirm this observation. 
Previous literature on the association of the majority of APO variables and 
cardiovascular disease risk factors have primarily been in adults (Gerber et al., 2002; 
Huang et al., 2013; Kei et al., 2012; Ooi et al., 2008; Sacks et al., 2000; Schaefer et al., 
1994; Sniderman et al., 2007, 2016; Steffen et al., 2017; Stewart et al., 2007; Zivanovic et 
al., 2018). Notably, these studies have reported that decreased concentrations of APO-AI, 
APO-AII, and APO-E and increased concentrations of APO-B100, APO-B100:AI ratio, and  
APO-CII may play a role in the risk of cardiovascular disease (Kappelle et al., 2011; Kei 
et al., 2012; McQueen et al., 2008; Pischon et al., 2005; Sharrett et al., 1994; Sniderman 
et al., 2007, 2016; Stewart et al., 2007). However, previous literature in children have 
predominately focused on concentrations of APO-AI and APO-B100. This could be due to 
the concentration of APO-AI represents the number of proatherogenic lipoproteins. 
Whereas, the concentrations of APO-B100 is a direct measure of the number of 
atherogenic lipoproteins. Specifically, these studies conducted have explored the 
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relationship between APO concentrations in children of parents who had either early 
onset coronary heart disease, history of cardiovascular disease, or myocardial infarction. 
These studies reported children of patients had lower concentrations of APO-AI and 
APO-AII, and higher APO-B100 and APO-B100:AI ratio (Beigel et al., 1993; Bornaun et 
al., 2017; Freedman et al., 1986; Uiterwaal et al., 1996).  
In addition, previous studies in children have explored APO-AI and APO-B100 
concentrations across BMI (Hobkirk et al., 2013; Krekoukia et al., 2007; Teixeira et al., 
2001). These studies report associations of APO-AI and APO-B100 with adiposity. 
Specifically, lower levels of APO-AI and higher levels of APO-B100 in children with 
obesity compared to their counterparts without obesity have been reported (Krekoukia et 
al., 2007; Teixeira et al., 2001). This is important since childhood obesity affects vascular 
structure and function and ultimately may increase the risk of cardiovascular disease 
(Dengel & Bronas, 2010). Therefore, the current understanding from the literature is that 
APOs may have minimal impact during childhood and adolescence but can predispose 
such individuals to substantial increased risk of cardiovascular disease in adulthood. 
To date, few studies conducted in adults and children have explored the 
association between APOs and measures of vascular structure and function. In adults, 
patients with increased cIMT had higher mean APO-B100 and APO-B100:AI ratio and 
lower APO-AI, with the most significant predictor of increased cIMT being the APO-
B100:AI ratio (Sharrett et al., 1994; Wallenfeldt et al., 2004; Zivanovic et al., 2018). 
Similarly, in children, studies reported that adulthood cIMT was inversely related with 
APO-AI and positively associated with APO-B100 and APO-B100:AI ratio (Frontini et al., 
2008; Juonala et al., 2008; Kallio et al., 2010). However, two of these studies were part of 
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long-term cohort studies that started in childhood, but the researchers obtained ultrasound 
measures of cIMT in adulthood (Frontini et al., 2008; Juonala et al., 2008). The current 
study explores the relationship of cIMT and a variety of APO variables, not just APO-AI 
and APO-B100. Interestingly, our study found no association between cIMT and any of 
the APO variables after post-hoc adjustment. These differences between study results 
could be influenced by the heterogeneity of the population and differences in geographic 
location. Therefore, the differences in cohorts and the effects of time may be the reason 
the present study’s observations were different. Also, APOs may have either a small 
impact on childhood cIMT or the effects on cIMT are not present yet at an early stage of 
disease. 
The effect of APOs on vascular health has predominately been restricted to 
analysis of flow-mediated dilation. These studies examining APO concentrations in 
relation to flow-mediated dilation have reported a strong positive correlation between 
flow-mediated dilation and APO-AI concentration in children with obesity, and a direct 
relationship between APO-AI and adulthood flow-mediated dilation (Juonala et al., 2008; 
Tounian et al., 2001). These results indicate a possible relationship between low APO-AI 
levels and endothelial dysfunction in children and the potential future effects of APO 
concentrations. While flow-mediated dilation is a measure of vascular function, 
specifically endothelial dysfunction of the brachial artery, this measure was not used in 
the present study. Instead, the present study assessed vascular function via applanation 
tonometry. Through this measurement multiple arteries can be evaluated (i.e., carotid, 
radial, femoral). However, in the current study we assessed the carotid and radial artery, 
and observed a significant positive association with PWV and APO-AII and APO-E. 
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Also, after further adjustment for body fat percent, a significant positive association with 
PWV and APO-E. These data may indicate these specific APOs may impact vascular 
function early in life. Notably, the opposing roles of APO-AII in lipoprotein metabolism 
(i.e., increased lecithin-cholesterol acyltransferase, decreased hepatic lipase and 
cholesteryl ester transfer protein) provide conflicting evidence in regard to cardiovascular 
disease risk. In addition, APO-E regulates the metabolism of lipoprotein containing APO-
B. Therefore, depending on the concentration of APO-E and the specific genotype, there 
may be more low-density lipoprotein cholesterol. Ultimately impacting arterial stiffness. 
Therefore, the complex roles of APO-AII and APO-E may explain why the present 
study’s observations may be different than previous studies.    
While the current study evaluated the effect of APO variables, and not age or 
body fat, on arterial structure and stiffness, we report that changes indicative of increased 
arteriosclerosis risk occurs first with measures of arterial stiffness. Specifically, PWV 
was impacted prior to other measures of vascular function (i.e., cCSC, cDC, cCSD, cDD, 
cIEM). However, this may be due to the differences in measures. The ultrasound derived 
measures were used for the carotid artery. While, applanation tonometry measures were 
from two sites, the radial and carotid artery. Previous studies have reported that signs of 
atherosclerosis occur at multiple vascular beds and the development of lesions at each 
bed is dependent on a variety of factors (i.e., genetic background, gender, oxidative 
stress) (Frangos, Gahtan, & Sumpio, 1999; VanderLaan, Reardon, & Getz, 2004). In 
addition, ultrasound derived measures provide images of the carotid artery as two 
dimensional and is a measure of regional vascular function. Whereas, applanation 
tonometry uses the sensor in the tonometer and pressure of the artery to provide 
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information on the pulse waveform. Therefore, PWV uses waveform travel between two 
sites and provides a measure of systemic arterial stiffness (Nelson et al., 2010; O’Rourke 
et al., 2002). Hence, the differences in measures may factor into why there were 
associations with PWV and not the ultrasound derived measures of vascular function. 
Strengths of this study include the relatively large sample size, inclusion of 
participants with a wide range of BMI values, the use of dual X-ray absorptiometry for 
measures of body composition, and the use of standardized methods used for measuring 
subclinical vascular structure and function. Limitations include the cross-sectional nature 
of the study, which prevents us from suggesting causality between APO concentrations 
and either increased or decreased cIMT, cCSC, cDC, cCSD, cDD, cIEM, or PWV or 
potential changes in these associations over time. It is also important to note that neither 
categories nor percentiles exist for APO concentrations, which limits the ability to 




CHAPTER 6: CONCLUSION 
In summary, these findings suggest higher levels of APO-E are associated with 
higher systemic arterial stiffness in children and adolescents, both with and without the 
adjustment for body fat percent. This study reported that APO-E may exert its effects on 
vascular function, specifically arterial stiffness, before altering vascular structure. 
However, further investigation of APOs as biomarkers for vascular structure in pediatrics 
is warranted. Also, future research is needed to assess how APO concentrations change 
over the childhood and adolescence period and the potential impact of body fat or 
















Table 1. Cohort demographics and anthropometrics 
 Overall Male Female 
N 338 160 178 
Race/Ethnicity: 
-African American or Black 34 (10.1%) 14 (8.8%) 20 (11.2%) 
-White 260 (76.9%) 123 (76.9%) 137 (77.0%) 
-Other 44 (13.0%) 23 (14.4%) 21 (11.8%) 
- Latino/Hispanic 38 (11.2%) 20 (12.5%) 18 (10.1%) 
Tanner Stage: 
-Stage I 85 (25.1%) 51 (31.9%) 34 (19.1%) 
-Stage II/III/IV 182 (53.8%) 78 (48.8%) 104 (58.4%) 
-Stage V 57 (16.9%) 24 (15.0%) 33 (18.5%) 
Obesity Status: 
-Normal 132 (39.1%) 75 (46.9%) 57 (32.0%) 
-Overweight 24 (7.1%) 10 (6.2%) 14 (7.9%) 
-Obesity 69 (20.4%) 32 (20.0%) 37 (20.8%) 
-Severe Obesity 113 (33.4%) 43 (26.9%) 70 (39.3%) 
Age (years) 13.0 (2.77) 13.0 (2.52) 13.0 (2.99) 
Weight (kg) 68.6 (29.9) 67.6 (32.0) 69.5 (27.9) 
Height (cm) 157 (14.1) 160 (15.5) 155 (12.4) 
BMI (kg/m2) 26.8 (8.92) 25.4 (8.8) 28.0 (8.87) 
BMI Percentile (%) 78.2 (27.8) 74.7 (28.4) 81.4 (27.0) 
Body Fat Percent (%) 36.8 (11.7) 32.5 (12.2) 40.7 (9.72) 
Continuous variables are presented as mean +/- standard deviation (SD). 
Categorical variables (e.g., race, Tanner stage, obesity status) are presented as count (% within column). 
Obesity status is presented as normal weight, overweight, obesity, severe obesity 
All who are missing BMI or any apolipoprotein measure were excluded 




Table 2. Associations of apolipoprotein variables with measures of vascular structure   
 Model 1 Model 2 










APO AI 0 (0, 0.001) 0.535 >0.999 0 (-0.001, 0.001) 0.728 >0.999 
APO AII 0.001 (0, 0.002) 0.172 >0.999 0.001 (0, 0.002) 0.194 >0.999 
APO B100 0 (-0.001, 0) 0.454 >0.999 0 (0, 0) 0.908 >0.999 
APO CII -0.003 (-0.005, 0) 0.02 0.924 -0.002 (-0.004, 0) 0.059 >0.999 
APO CIII -0.001 (-0.002, 0.001) 0.326 >0.999 0 (-0.001, 0.001) 0.548 >0.999 
APO E 0.001 (-0.004, 0.006) 0.663 >0.999 0.003 (-0.003, 0.008) 0.309 >0.999 
APO B100:AI 0 (-0.001, 0.001) 0.936 >0.999 0 (0, 0.001) 0.362 >0.999 
APO CIII:CII 0.001 (0, 0.003) 0.033 >0.999 0.001 (0, 0.003) 0.049 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 







Table 3. Associations of apolipoprotein variables with measures of carotid cross-sectional compliance  
 Model 1 Model 2 









cCSC (1/mmHg x 10-3) 
APO AI -0.01 (-0.02, 0.01) 0.366 >0.999 -0.1 (-0.03, -0.002) 0.086 >0.999 
APO AII -0.02 (-0.05, 0.02) 0.326 >0.999 -0.02 (-0.05, 0.01) 0.268 >0.999 
APO B100 -0.01 (-0.02, 0.004) 0.186 >0.999 -0.004 (-0.02, 0.01) 0.454 >0.999 
APO CII -0.04 (-0.09, 0.02) 0.202 >0.999 -0.03 (-0.08, 0.03) 0.343 >0.999 
APO CIII -0.02 (-0.05, 0.004) 0.089 >0.999 -0.02 (-0.05, 0.01) 0.149 >0.999 
APO E -0.04 (-0.17, 0.08) 0.501 >0.999 -0.02 (-0.14, 0.11) 0.765 >0.999 
APO B100:AI -0.003 (-0.02, 0.01) 0.704 >0.999 0.003 (-0.01, 0.02) 0.658 >0.999 
APO CIII:CII -0.01 (-0.04, 0.02) 0.407 >0.999 -0.01 (-0.04, 0.02) 0.352 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 






Table 4. Associations of apolipoprotein variables with measures of carotid diameter compliance  
 Model 1 Model 2 









cDC (mm/mmHg x 10-3) 
APO AI -0.03 (-0.07, 0.02) 0.208 >0.999 -0.04 (-0.08, -0.001) 0.044 >0.999 
APO AII -0.04 (-0.12, 0.03) 0.279 >0.999 -0.05 (-0.13, 0.03) 0.228 >0.999 
APO B100 -0.02 (-0.05, 0.003) 0.076 >0.999 -0.02 (-0.05, 0.01) 0.206 >0.999 
APO CII -0.07 (-0.21, 0.07) 0.319 >0.999 -0.05 (-0.19, 0.09) 0.489 >0.999 
APO CIII -0.05 (-0.12, 0.02) 0.165 >0.999 -0.04 (-0.11, 0.03) 0.25 >0.999 
APO E -0.10 (-0.41, 0.21) 0.52 >0.999 -0.05 (-0.36, 0.26) 0.753 >0.999 
APO B100:AI -0.003 (-0.04, 0.03) 0.87 >0.999 0.01 (-0.03, 0.05) 0.549 >0.999 
APO CIII:CII -0.03 (-0.1, 0.05) 0.52 >0.999 -0.03 (-0.10, 0.05) 0.461 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 







Table 5. Associations of apolipoprotein variables with measures of carotid cross-sectional distensibility  
 Model 1 Model 2 










APO AI -0.05 (-0.11, 0.01) 0.084 >0.999 -0.06 (-0.12, 0.01) 0.055 >0.999 
APO AII -0.06 (-0.17, 0.05) 0.288 >0.999 -0.06 (-0.17, 0.05) 0.272 >0.999 
APO B100 -0.02 (-0.06, 0.02) 0.387 >0.999 -0.02 (-0.06, 0.02) 0.441 >0.999 
APO CII -0.07 (-0.27, 0.13) 0.481 >0.999 -0.07 (-0.26, 0.13) 0.52 >0.999 
APO CIII -0.04 (-0.14, 0.05) 0.384 >0.999 -0.04 (-0.14, 0.06) 0.409 >0.999 
APO E 0.06 (-0.39, 0.50) 0.807 >0.999 0.07 (-0.38, 0.51) 0.773 >0.999 
APO B100:AI 0.03 (-0.02, 0.09) 0.207 >0.999 0.04 (-0.01, 0.10) 0.145 >0.999 
APO CIII:CII -0.04 (-0.14, 0.07) 0.512 >0.999 -0.04 (-0.14, 0.07) 0.499 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 








Table 6. Associations of apolipoprotein variables with measures of carotid diameter distensibility  
 Model 1 Model 2 










APO AI -0.02 (-0.04, 0.01) 0.172 >0.999 -0.02 (-0.05, 0.01) 0.123 >0.999 
APO AII -0.02 (-0.07, 0.03) 0.386 >0.999 -0.02 (-0.07, 0.03) 0.366 >0.999 
APO B100 -0.004 (-0.02, 0.01) 0.63 >0.999 -0.003 (-0.02, 0.01) 0.703 >0.999 
APO CII -0.02 (-0.11, 0.06) 0.615 >0.999 -0.02 (-0.10, 0.07) 0.659 >0.999 
APO CIII -0.01 (-0.05, 0.03) 0.572 >0.999 -0.01 (-0.05, 0.03) 0.603 >0.999 
APO E 0.01 (-0.18, 0.20) 0.916 >0.999 0.01 (-0.18, 0.21) 0.883 >0.999 
APO B100:AI 0.01 (-0.01, 0.04) 0.244 >0.999 0.02 (-0.01, 0.04) 0.175 >0.999 
APO CIII:CII -0.01 (-0.06, 0.03) 0.582 >0.999 -0.01 (-0.04, 0.02) 0.568 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 







Table 7. Associations of apolipoprotein variables with measures of carotid incremental elastic modulus 
 Model 1 Model 2 










APO AI -0.57 (-3.26, 2.11) 0.674 >0.999 0.95 (-1.70, 3.61) 0.481 >0.999 
APO AII -0.17 (-5.33, 4.99) 0.948 >0.999 0.22 (-4.76, 5.19) 0.932 >0.999 
APO B100 1.24 (-0.56, 3.04) 0.176 >0.999 0.45 (-1.32, 2.22) 0.615 >0.999 
APO CII 4.27 (-4.83, 13.37) 0.356 >0.999 1.94 (-6.89, 10.77) 0.666 >0.999 
APO CIII 2.57 (-1.86, 6.99) 0.255 >0.999 1.63 (-2.66, 5.91) 0.456 >0.999 
APO E -0.68 (-21.22, 19.87) 0.948 >0.999 -6.82 (-26.81, 13.17) 0.503 >0.999 
APO B100:AI 1.09 (-1.38, 3.56) 0.385 >0.999 -0.42 (-2.87, 2.04) 0.739 >0.999 
APO CIII:CII 0.69 (-4.27, 5.64) 0.785 >0.999 1.01 (-3.77, 5.79) 0.678 >0.999 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 







Table 8. Associations of apolipoprotein variables with measures of vascular stiffness 
 Model 1 Model 2 









Radial-carotid PWV (m/s) 
APO AI 0.02 (0.01, 0.03) 0.003 0.463 0.02 (0.01, 0.03) 0.004 0.516 
APO AII 0.04 (0.02, 0.06) <0.001 0.046 0.04 (0.02, 0.06) <0.001 0.054 
APO B100 0.01 (0.002, 0.02) 0.012 >0.999 0.01 (0.003, 0.02) 0.008 >0.999 
APO CII 0 (-0.04, 0.04) 0.986 >0.999 0.001 (-0.03, 0.04) 0.943 >0.999 
APO CIII 0.02 (-0.002, 0.03) 0.078 >0.999 0.02 (-0.001, 0.03) 0.072 >0.999 
APO E 0.16 (0.08, 0.24) <0.001 0.012 0.16 (0.08, 0.24) <0.001 0.010 
APO B100:AI -0.01 (-0.02, 0.001) 0.067 >0.999 -0.01 (-0.02, 0.001) 0.078 >0.999 
APO CIII:CII 0.03 (0.01, 0.05) <0.001 0.085 0.03 (0.01, 0.05) <0.001 0.091 
Model 1 is adjusted for Tanner stage, sex, and race; Model 2 further adjusts Model 1 for body fat percent. Adjusted p-values were calculated using Holm’s 
method. 
Data presented are mean difference and 95% confidence interval estimates for each apolipoprotein. Additionally, apolipoproteins are scaled to 10 µg/mL and 
ratios were scaled to 0.1 µg/mL. 
Abbreviations: PWV = Pulse wave velocity 
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